期刊文献+

甘草酸二铵注射液预防化疗引起的肝功能异常的效果 被引量:4

Prophylatic Effect of Diammonii Glycyrrhizinatis on Hepatic Disfunction Caused by Chemotherapy:a Randomized Cross-over Study
下载PDF
导出
摘要 目的 :探讨甘草酸二铵注射液对恶性肿瘤患者全身化疗所致肝损害的防治效果。方法 :10 0例患者采用自身对照 ,每例用同一化疗方案连续化疗 2周期 ,其中一周期单纯化疗 ,另一周期化疗同时加用甘草酸二铵注射液 ;观察化疗后肝功能变化。结果 :两周期化疗后谷氨酸转氨酶升高分别为 15 0 % ,5 0 % (χ2 =5 5 5 6 ,P =0 0 18) ;谷氨酰胺转移酶升高13 0 % ,5 0 % (χ2 =3 90 7,P =0 0 4 8)。加用甘草酸二铵周期的肝功能损害的发生率明显减少。结论 Objective :To evaluate the effect of Diammonii Glycyrrhizinatis in preventing liver damage caused by chemotherapeutic agents.Methods:Using cross-over study method,100 patients with malignant tumor were recruited in this clinical trial.Diammonii Glycyrrhizinatis was used as self-control in the previous or next course of chemotherapy in the same patient.Each patient was treated with chemotherapy alone for one cycle,and chemotherapy in combination with Diammonii Glycyrrhizinatis injection for the other.The change of liver function was observed.Results:The incidences of ALT elevation were 15.0% and 5.0%,respectively(χ 2=5.556,P=0.018),and the corresponding rates of GGT elevation were 13.0% and 5.0%,respectively(χ 2=3.907,P=0.048)in chemotherapy and combination groups.The abnormality of liver function was less in the combination group.Conclusion:Diammonii Glycyrrhizinatis is effective for preventing hepatic damage induced by chemotherapeutic agents.
出处 《汕头大学医学院学报》 2004年第2期78-79,共2页 Journal of Shantou University Medical College
关键词 甘草酸二铵注射液 预防 化疗 肝功能异常 恶性肿瘤 Neoplasm,Drug Therapy Liver Disease,Chemically Induced Glycyrrhizic Acid,Therapeutic Use
  • 相关文献

参考文献3

  • 1Steinberg JL,Yeo W,Zhong S,et al.Hepatitis B virus reactivation in patients undergoing cytoxoxic chemotherapy for solid tumours:precore/core mutations may play an important role[J].J Med Virol,2000,60(3):249-255.
  • 2王伟莉 罗小克 桑晓君.甘利欣注射液防治抗结核药所致肝损害的临床观察.中国医院药学杂志,1999,19(2):102-103.
  • 3林雯,林英城,王鸿彪,林懿,郑毓武.乙肝病毒阳性的实体瘤患者化疗期间肝功能变化[J].肿瘤防治杂志,2002,9(3):293-295. 被引量:3

二级参考文献7

  • 1[1]Arshad HM, William ML. Chronic hepatitis B virus infection: treatment strategies fir the next millennium [J]. Ann Intern Med ,2000,132(9):723 - 731.
  • 2[2]Kumagai K,Takagi T,Nakamura S,et al. Hepatitis B virus carriers in the treatment of malignant lymophoma: an epidemilogical study in Japan[J]. Ann Oncol, 1999,8(Suppl 1): 107 - 109.
  • 3[3]Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cyctotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors[J].Med Virol ,2000,62(3) :299 - 307.
  • 4[4]Markovic S, Drozina G, Vork M, et al. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy: A prospective study in 305 patients [J]. Hepatogastroenterology, 1999,46(29) :2925 - 2930.
  • 5[5]Alexopoulos CG,Vaslamatzis M,Hatzidumitrion G.Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours [J]. Br J Cancer, 1999,81(1):69-74.
  • 6[6]Nakamura K, Motokuru T, Fujita A, et al. Severe hepatitis related to chemotherapy in Hepatitis B virus carriers with hematologic malignancies[J].Cancer, 1996,78(10) :2210 - 2215.
  • 7[7]Yeo W,Steinberg JL,Tam JS,et al. Lamividine in the treatment of hepatitis B virus reactivation dttring cytotoxic chemotherapy[J].J Med Virol, 1999,59(3) :263 - 269.

共引文献6

同被引文献112

引证文献4

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部